How High Cholesterol Raises the Risk of Heart Disease

Cholesterol Is Not the Enemy — Uncontrolled LDL Is

Cholesterol is an essential molecule. Every cell membrane in the human body depends on it for structural integrity. Cholesterol is the precursor to steroid hormones, bile acids, and vitamin D. The liver synthesizes approximately 80% of the body's cholesterol, with only 20% coming from diet. The problem arises not from cholesterol itself, but from how much low-density lipoprotein (LDL) is circulating in blood and how long it remains there. The Framingham Heart Study — which has tracked cardiovascular risk factors in a Massachusetts community since 1948 — established that for every 1 mmol/L (38.7 mg/dL) increase in LDL cholesterol, the risk of major coronary events rises by approximately 30%.

Lipoproteins: Cholesterol Transport Vehicles

Because cholesterol is a fat and blood is water-based, cholesterol must be transported packaged in lipoproteins — protein-coated spherical particles. Different lipoprotein classes carry cholesterol in different directions and with different cardiovascular consequences.

How LDL Enters the Arterial Wall

The atherosclerotic process begins with LDL particles crossing the endothelium — the single-cell lining of arteries — and becoming retained in the subendothelial space. LDL retention is not passive; LDL particles bind to proteoglycans in the arterial matrix. Once trapped, LDL is oxidized by reactive oxygen species generated by local inflammatory cells. This is the critical trigger. Oxidized LDL (oxLDL) is not recognized by normal LDL receptors — instead, it is taken up by macrophages through scavenger receptors, bypassing normal feedback regulation.

Macrophages engulf oxLDL continuously, becoming engorged with cholesterol droplets and transforming into foam cells. Accumulations of foam cells form a fatty streak — the earliest visible lesion of atherosclerosis, present in some individuals as young as ten years old. Over decades, the fatty streak evolves into an atherosclerotic plaque containing a lipid-rich necrotic core, fibrous cap, smooth muscle cells, calcified deposits, and inflammatory infiltrates.

Plaque Rupture and Heart Attack

Not all plaques are equally dangerous. The fibrous cap overlying the lipid core can rupture when it becomes thin — a process driven by matrix metalloproteinases (MMPs) secreted by macrophages in the plaque. Cap rupture exposes the thrombogenic lipid core to flowing blood, triggering immediate platelet aggregation and thrombus formation. Acute coronary syndrome — unstable angina, NSTEMI, or STEMI — occurs when this thrombus obstructs the coronary artery lumen.

• The most dangerous plaques are not the largest — large, calcified plaques may be stable and produce only stable angina
• High-risk (vulnerable) plaques have thin fibrous caps (below 65 micrometers), large lipid cores, and high macrophage density
• Statin therapy stabilizes plaques by reducing macrophage infiltration and increasing fibrous cap thickness, even when LDL is only modestly reduced

Cholesterol Targets and Risk Assessment

Risk is not determined by total cholesterol alone. Absolute cardiovascular risk — calculated using tools like the Pooled Cohort Equations (American College of Cardiology/AHA) or SCORE2 (European) — integrates LDL, HDL, blood pressure, smoking status, diabetes, age, and sex to estimate 10-year cardiovascular event probability.

Causes of Elevated LDL

• Familial hypercholesterolemia (FH): a dominant genetic disorder affecting approximately 1 in 250 people globally; caused by mutations in the LDL receptor, ApoB, or PCSK9 genes; results in markedly elevated LDL from birth and premature atherosclerosis
• Diet high in saturated and trans fats: saturated fatty acids downregulate hepatic LDL receptor expression, reducing LDL clearance from blood
• Hypothyroidism: reduces LDL receptor activity and slows cholesterol catabolism
• Type 2 diabetes and insulin resistance: increase VLDL production and produce small, dense LDL particles that are more atherogenic per particle
• Nephrotic syndrome: protein loss triggers compensatory liver lipoprotein overproduction

Treatment

Statins remain the most rigorously tested LDL-lowering drugs. They inhibit HMG-CoA reductase — the rate-limiting enzyme in cholesterol synthesis — reducing hepatic cholesterol production. This upregulates LDL receptors on liver cells, increasing LDL clearance from blood. High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) reduce LDL by 50% or more.

• PCSK9 inhibitors (alirocumab, evolocumab): monoclonal antibodies that prevent degradation of LDL receptors, dramatically reducing LDL by 50–60% on top of statin therapy; indicated for FH and statin-intolerant very-high-risk patients
• Ezetimibe: blocks intestinal cholesterol absorption; additive to statin therapy; reduces LDL by 15–20% additionally
• Bempedoic acid: an ACL inhibitor that reduces hepatic cholesterol synthesis upstream of HMG-CoA reductase; useful in statin-intolerant patients
• Inclisiran: siRNA drug that silences hepatic PCSK9 mRNA; administered every 6 months via injection; reduces LDL by approximately 50%

This article is for informational purposes only. Consult a qualified healthcare professional for medical advice.